Arrowhead Pharmaceuticals (ARWR) Assets Average (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 16 years of Assets Average data on file, last reported at $1.9 billion in Q1 2026.

• Quarterly Assets Average rose 49.68% year-over-year to $1.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 49.68% YoY) and the FY2025 annual result came in at $1.3 billion, up 32.53% from the prior year.
• Assets Average improved to $1.9 billion in Q1 2026, from $1.5 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.9 billion in Q1 2026 to a low of $671.1 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $891.4 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average slipped 12.1% — and 2025, when it soared 63.6%.
• Tracing ARWR's Assets Average over 5 years: stood at $791.7 million in 2022, then declined by 12.1% to $695.9 million in 2023, then jumped by 54.72% to $1.1 billion in 2024, then surged by 38.82% to $1.5 billion in 2025, then grew by 29.54% to $1.9 billion in 2026.
• The last three Assets Average figures came in at $1.9 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.